| Literature DB >> 22142904 |
Olivier Boucher1, Matthew J Burden, Gina Muckle, Dave Saint-Amour, Pierre Ayotte, Éric Dewailly, Charles A Nelson, Sandra W Jacobson, Joseph L Jacobson.
Abstract
BACKGROUND: Lead (Pb) and polychlorinated biphenyls (PCBs) are neurotoxic contaminants that have been related to impairment in response inhibition.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22142904 PMCID: PMC3339450 DOI: 10.1289/ehp.1103828
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Descriptive statistics for the study sample (n = 196).
| Variables | Mean ± SD | Median | Range | Percent | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Child age at assessment (years) | 196 | 11.3 ± 0.6 | 11.4 | 9.8–12.9 | ||||||
| Child sex (% girls) | 196 | 55.1 | ||||||||
| Adoption status (% adopted) | 196 | 15.8 | ||||||||
| Transportation by plane (% yes) | 196 | 45.4 | ||||||||
| Time at ERP assessment (% morning) | 196 | 53.1 | ||||||||
| Maternal characteristics | ||||||||||
| Age at delivery (years) | 196 | 23.9 ± 5.8 | 22.0 | 15–42 | ||||||
| Marital status (% single) | 195 | 25.1 | ||||||||
| Education (years) | 196 | 8.3 ± 2.6 | 8.5 | 0–16 | ||||||
| Hollingshead score | 196 | 28.9 ± 12.4 | 28.5 | 8.0–66.0 | ||||||
| Raven score | 196 | 35.1 ± 10.1 | 37.0 | 4–56 | ||||||
| Breast-feeding duration | 190 | 16.0 ± 17.5 | 11.5 | 0.1–108.0 | 68.4 | |||||
| Maternal use or consumption during pregnancy | ||||||||||
| Cigarettes (% yes) | 189 | 82.0 | ||||||||
| Marijuana (% yes) | 160 | 21.3 | ||||||||
| Binge drinking (≥ 5 standard drinks of alcohol per occasion; % yes) | 160 | 31.3 | ||||||||
| Contaminants and other biological samples | ||||||||||
| Cord blood Pb (μg/dL) | 193 | 4.8 ± 3.4 | 3.7 | 0.8–20.9 | ||||||
| Current blood Pb (μg/dL) | 193 | 2.6 ± 2.2 | 2.0 | 0.4–12.8 | ||||||
| Cord plasma PCB-153 (μg/kg fat) | 191 | 117.7 ± 90.9 | 93.3 | 9.7–653.6 | ||||||
| Current plasma PCB-153 (μg/kg fat) | 192 | 72.0 ± 70.7 | 45.7 | 3.5–431.4 | ||||||
| Cord blood Hg (μg/L) | 193 | 21.2 ± 17.6 | 16.6 | 1.0–99.3 | ||||||
| Current blood Hg (μg/L) | 193 | 4.6 ± 5.1 | 2.8 | 0.1–34.1 | ||||||
| Cord plasma DHA (% phospholipids) | 189 | 3.7 ± 1.3 | 3.5 | 1.1–7.7 | ||||||
| Current plasma DHA (% phospholipids) | 191 | 2.4 ± 1.0 | 2.2 | 0.1–5.5 | ||||||
| Go/no-go behavioral performance | ||||||||||
| Mean RT, correct go trials (msec) | 196 | 479.2 ± 75.8 | 472.0 | 322.0–720.0 | ||||||
| Mean RT, incorrect no-go trials (msec) | 196 | 419.5 ± 87.2 | 403.0 | 271.0–718.0 | ||||||
| Correct go trials (%) | 196 | 90.1 ± 9.7 | 93.2 | 52–100 | ||||||
| Correct no-go trials (%) | 196 | 64.0 ± 14.9 | 66.7 | 22–94 | ||||||
Intercorrelations among contaminants (Pearson correlation coefficients, r).
| Pb | PCB-153 | Hg | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemical | Sample | Cord | Current | Cord | Current | Cord | Current | |||||||
| Pb | Cord | 1.00 | 0.17** | 0.28* | 0.29* | 0.32* | 0.18** | |||||||
| Current | 1.00 | 0.04 | 0.25* | 0.12 | 0.23* | |||||||||
| PCB-153 | Cord | 1.00 | 0.45* | 0.42* | 0.25* | |||||||||
| Current | 1.00 | 0.41* | 0.55* | |||||||||||
| Hg | Cord | 1.00 | 0.46* | |||||||||||
| Current | 1.00 | |||||||||||||
| * | ||||||||||||||
Associations between contaminants and behavioral performance in the go/no-go task (n = 196).
| Pb | PCB-153 | Hg | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cord blood | Current blood | Cord plasma | Current plasma | Cord blood | Current blood | |||||||||||||
| Behavioral outcome | β | β | β | β | β | β | ||||||||||||
| Mean RT, correct go trials | 0.06 | –0.05 | –0.01 | 0.03 | 0.15** | 0.04 | 0.17** | 0.18** | 0.13# | 0.04 | 0.15** | 0.10 | ||||||
| Mean RT, incorrect no-go trials | 0.14# | 0.10 | 0.01 | 0.03 | 0.16** | 0.07 | 0.17** | 0.06 | 0.10 | 0.03 | 0.20* | 0.11 | ||||||
| Percent correct go | –0.12# | –0.21** | –0.11 | –0.12 | –0.01 | 0.03 | –0.06 | –0.01 | –0.03 | 0.06 | –0.11 | –0.02 | ||||||
| Percent correct no-go | –0.16** | –0.17** | –0.20* | –0.16** | 0.05 | 0.06 | –0.12 | –0.06 | –0.06 | 0.07 | –0.07 | –0.03 | ||||||
| Values are Pearson correlation ( | ||||||||||||||||||
Figure 1Mean ± SD behavioral performance in the go/no-go task according to quartiles of exposure: (A,B) cord blood Pb, (C) 11-year blood Pb, and (D) 11-year plasma PCB‑153. Outcome measures are adjusted for the potential confounders listed in Table 3.
Associations between contaminants and stimulus-locked ERP components recorded during the go/no-go task (n = 193).
| Pb | PCB-153 | Hg | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cord blood | Current blood | Cord plasma | Current plasma | Cord blood | Current blood | |||||||||||||||||||
| ERP parameter | β | β | β | β | β | β | ||||||||||||||||||
| N2 (Fz) | ||||||||||||||||||||||||
| Go latency | –0.01 | 0.08 | 0.05 | 0.02 | 0.09 | 0.15#a | 0.05 | 0.08 | 0.08 | 0.05 | 0.01 | 0.02 | ||||||||||||
| No-go latency | –0.03 | –0.01 | 0.01 | –0.01 | 0.01 | –0.11 | 0.14# | 0.01 | 0.09 | 0.04 | 0.16** | 0.11 | ||||||||||||
| Go amplitude | 0.03 | 0.08 | 0.02 | 0.02 | –0.03 | 0.00 | 0.01 | 0.07 | 0.09 | 0.13#d,j | 0.01 | 0.06 | ||||||||||||
| No-go amplitude | –0.00 | 0.02 | 0.00 | 0.05 | –0.05 | –0.01 | 0.04 | 0.01 | 0.02 | 0.03 | 0.04 | 0.02 | ||||||||||||
| P3 (Pz) | ||||||||||||||||||||||||
| Go amplitude | –0.06 | –0.05 | –0.20* | –0.16** | 0.03 | 0.08 | –0.13# | –0.01 | –0.08 | –0.02 | –0.21* | –0.15#n,o | ||||||||||||
| No-go amplitude | –0.06 | –0.06 | –0.26* | –0.23* | 0.04 | 0.12 | –0.13# | –0.01 | –0.14# | –0.10 | –0.18** | –0.06 | ||||||||||||
| Values are Pearson correlation ( | ||||||||||||||||||||||||
Figure 2Grand average for stimulus-locked go/no-go ERPs at midline electrodes comparing participants from the first quartile of blood Pb concentrations at time of testing (range, 0.4–1.3 μg/dL; n = 47; thin lines) and those from the fourth quartile (range, 2.9–12.8 μg/dL; n = 48; thick lines) for go (solid lines) and no-go (dashed lines) trials. The N2 is the second negative component (~ 375 msec), which is more pronounced at the frontal lead (Fz). The P3 peaks around 500 msec and is larger at the parietal lead (Pz). Children with higher blood Pb concentrations show reduced activity during the P3 time window compared with children with lower Pb levels.
Associations between contaminants and response-locked ERP amplitudes recorded during the go/no-go task (n = 166).
| Pb | PCB-153 | Hg | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cord blood | Current blood | Cord plasma | Current plasma | Cord blood | Current blood | |||||||||||||||||||
| ERP parameter | β | β | β | β | β | β | ||||||||||||||||||
| ERN (FCz) | 0.03 | –0.02 | 0.09 | 0.11 | 0.07 | –0.03 | 0.06 | 0.02 | 0.12 | 0.11 | 0.10 | 0.07 | ||||||||||||
| Pe (Cz) | –0.11 | –0.07 | –0.11 | –0.00 | 0.07 | 0.11 | –0.18** | –0.16** | –0.09 | 0.05 | –0.11 | –0.03 | ||||||||||||
| Pc (FCz) | –0.19** | –0.12 | –0.10 | –0.00 | –0.08 | –0.03 | –0.23* | –0.20** | –0.12 | 0.01 | –0.10 | 0.01 | ||||||||||||
| Values are Pearson correlation ( | ||||||||||||||||||||||||
Figure 3Grand average for response-locked go/no-go ERPs at midline electrodes comparing participants from the first quartile of plasma PCB-153 concentrations at time of testing (range, 3.5–26.0 μg/g fat; n = 46; thin lines) to those from the fourth quartile (range, 96.6–431.4 μg/g fat; n = 42; thick lines). Incorrect no-go trials (false alarms; dashed lines) elicit an early wave of negative voltage (ERN) followed by a large positive wave (Pe) maximal at the vertex (Cz). Correct go responses (solid lines) generate a frontocentral wave of positive voltage in the 100–300 msec (Pc) latency interval. Children with higher plasma PCB-153 concentrations show reduced activity during the Pe and Pc time windows compared with children with lower PCB-153 levels.